Managing atherogenic dyslipidaemia and diabetic retinopathy in type 2 diabetes

Description

In this Product Explainer, Endocrinologist Prof Richard O’Brien explains the role of Fenofibrate in reducing the progression of diabetic retinopathy in patients with type 2 diabetes (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Ted Wu

Dr Ted Wu

Cardiovascular Outcomes & GLP1 – An Update

Dr Alison Chiu

Dr Alison Chiu

Dry Eye – Practical Management Tips for Better Outcome

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Richard O'Brien

expert

Prof Richard O'Brien

Endocrinologist; Clinical Dean of Medicine, University of Melbourne, Austin Clinical School; Director of Graduate Programs, Melbourne Medical School; Senior Endocrinologist and Director, Lipid Service, Austin Health

Date published: 3 February 2023